Paul G. Allen Frontiers Group [to 5 Oct 2019]
A computational challenge to help developmental biology
October 1, 2019
Q&A with the scientists and organizers behind a new competition to use machine learning to reconstruct an entire animal’s developmental lineage


BMGF – Gates Foundation [to 5 Oct 2019]
No new digest content identified.


Bill & Melinda Gates Medical Research Institute [to 5 Oct 2019]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.


CARB-X [to 5 Oct 2019]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.


CEPI – Coalition for Epidemic Preparedness Innovations [to 5 Oct 2019]
No new digest content identified.


Clinton Health Access Initiative, Inc. (CHAI) [to 5 Oct 2019]
News & Press Releases
No new digest content identified.


EDCTP [to 5 Oct 2019]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
4 October 2019
EDCTP invests €18 million in evaluation of candidate malaria vaccine portfolio
EDCTP awarded a grant of EUR 18 million to an international consortium to evaluate a portfolio of three innovative candidate malaria vaccines that aim to block transmission of the Plasmodium falciparum parasite. The PfTBV consortium is coordinated by Dr Issaka Sagara from the University of Sciences, Techniques and Technologies in Bamako, Mali, with research sites in Burkina Faso, Guinea, Liberia and Mali. Two vaccines were developed by the Statens Serum Institute (SSI, Denmark), the third has been developed and will be produced through the National Institutes of Health in the US which also contributes a large financial investment. Additional co-funding is received from PATH in the US…


Emory Vaccine Center [to 5 Oct 2019]
Website not responding at inquiry


European Medicines Agency [to 5 Oct 2019]
News: EMA Management Board: highlights of October 2019 meeting


European Vaccine Initiative [to 5 Oct 2019]
02 October 2019
Initiation of Phase 1 Zika vaccine clinical trial
The ZIKAVAX consortium announced today the initiation of a Phase 1 clinical trial of a second-generation Zika vaccine. The vaccine candidate is based on one of the project partners -Themis- proprietary measles vector platform.


FDA [to 5 Oct 2019]
October 3, 2019 – FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic
The U.S. Food and Drug Administration today approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex. Descovy is not indicated in individuals at risk of HIV-1 infection from receptive vaginal sex because the effectiveness in this population has not been evaluated…


Fondation Merieux [to 5 Oct 2019]
No new digest content identified.


Gavi [to 5 Oct 2019]
Latest news
No new digest content identified.


GHIT Fund [to 5 Oct 2019]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that September 30, 2019
GHIT Fund Announces New Investments: A Total of 630 Million Yen in Drug for Malaria, Tuberculosis, Chagas disease, and Leishmaniasis, Vaccines for Malaria and Chagas disease, and Diagnostics for Malaria


Global Fund [to 5 Oct 2019]
News & Stories
Sweden Steps Up Fight Against Epidemics with Strong Pledge to Global Fund
03 October 2019

Funding Model
Further Resources and Materials Now Available for 2020-2022 Funding Cycle
03 October 2019

Norway Makes Strong Pledge to Global Fund
29 September 2019


Hilleman Laboratories [to 5 Oct 2019]
No new digest content identified.


Human Vaccines Project [to 5 Oct 2019]
Press Releases
No new digest content identified.


IAVI [to 5 Oct 2019]
No new digest content identified.



International Coalition of Medicines Regulatory Authorities (ICMRA)
Selected Statements, Press Releases, Research
Strategic Priority on Innovation – ICMRA Innovation Project 3D Bio-Printing Case Study: Summary of Discussions and Considerations for the New Informal Innovation Network
October 1, 2019 :: 3D Bio-Printing Case Study Report



No new digest content identified.


IFRC [to 5 Oct 2019]
Selected Press Releases, Announcements
Philippines: Red Cross scales up as polio threatens 11 million children
Manila/Kuala Lumpur/Geneva 2 October 2019 –  Polio has made an alarming come-back after officially being eradicated 19 years ago in the Philippines. The Philippine Red Cross and the International Federation of Red Cross and Red Crescent Societies (IFRC …
2 October 2019
[See Polio above for detail]


IVAC [to 5 Oct 2019]
No new digest content identified.


IVI [to 5 Oct 2019]
Selected IVI News & Announcements
No new digest content identified.


JEE Alliance [to 5 Oct 2019]
Selected News and Events
No new digest content identified.


MSF/Médecins Sans Frontières [to 5 Oct 2019]
Latest [Selected Announcements]
DRC Ebola outbreaks
Vaccinating against Ebola in a challenging context
Project Update 3 Oct 2019


National Vaccine Program Office – U.S. HHS [to 5 Oct 2019]
Request for Information (RFI) From Non-Federal Stakeholders: Developing the 2020 National Vaccine Plan
For nearly a decade the 2010 National Vaccine Plan (NVP) has served as the nation’s leading roadmap for enhancing all aspects of the U.S. vaccine and immunization system. To ensure the NVP remains nimble to the evolving vaccine and immunization landscape, the U.S. Department of Health and Human Services (HHS) is leading the development of the 2020 National Vaccine Plan. The updated plan will reflect immunization across the lifespan and guide priority actions for the period 2020-2025.
As part of that process, the HHS Office of Infectious Disease and HIV/AIDS Policy (OIDP) has issued a Request for Information to solicit input from subject matter experts and non-federal stakeholders on potential priorities, goals, and objectives for the plan.
We invite you to share your feedback on the Request for Information. Comments are due no later than 5:00 p.m., ET on October 24, 2019.
View the Request for Information and provide your feedback


NIH [to 5 Oct 2019]
Selected News Releases
NIH funding bolsters rare diseases research collaborations
October 3, 2019 — New grants aimed at better understanding diseases, moving potential treatments closer to the clinic.

In women with HIV, TB preventive therapy poses greater risk in pregnancy than postpartum
October 2, 2019 — Deferring drug until after delivery is safer, NIH-funded trial finds.

NIH researchers create new viral vector for improved gene therapy in sickle cell disease
October 2, 2019 — ‘Forward-oriented’ design might boost treatment effectiveness and broaden use.

New NIH-funded translational research centers to speed, diversify Alzheimer’s drug discovery
October 1, 2019 — Expanded open science will advance the pipeline for innovative therapeutics

NIH to fund hubs to accelerate development of biomedical health technologies
October 1, 2019 — Program links academic institutions developing best practices to translate biomedical innovations into public benefit.

NIH forms new collaborative influenza vaccine research network
September 30, 2019 — The CIVICs program is a new network of research centers that will work together to develop more durable, broadly protective and longer-lasting influenza vaccines.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has initiated the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program, a new network of research centers that will work together in a coordinated, multidisciplinary effort to develop more durable, broadly protective and longer-lasting influenza vaccines. NIAID will provide up to approximately $51 million in total first-year funding for the program, which is designed to support the CIVICs program centers over seven years.
“To more effectively fight influenza on a global scale, we need better influenza vaccines that are more broadly protective,” said NIAID Director Anthony S. Fauci, M.D. “With the CIVICs program we hope to encourage an exchange of ideas, technology and scientific results across multiple institutions to facilitate a more efficient and coordinated approach to novel influenza vaccine development.”…
The CIVICs network will develop so-called universal influenza vaccines, which could provide longer-lasting protection than current vaccines and against a wider variety of influenza viruses. The CIVICs centers will conduct multidisciplinary research that supports the development of vaccine candidates through testing in preclinical studies, clinical trials and human challenge studies. The CIVICs network also will explore approaches to improve seasonal influenza vaccines, such as by testing alternative vaccine platforms or incorporating new adjuvants (substances added to vaccines to boost immunity). These advances could substantially reduce influenza hospitalizations and deaths in the future.
The CIVICs program will include three Vaccine Centers, one Vaccine Manufacturing and Toxicology Core, two Clinical Cores, and one Statistical, Data Management, and Coordination Center (SDMCC)…


PATH [to 5 Oct 2019]
Selected Announcements
No new digest content identified.


ProMED [Program for Monitoring Emerging Diseases] [to 5 Oct 2019]
International Society for Infectious Diseases
Selected Announcements/Posts
No new digest content identified.


RoRI [Research on Research Institute] [to 5 Oct 2019]
We’re an open and independent new initiative providing data, analysis and intelligence on how to make research systems more strategic, open, diverse and inclusive.
News and Events
RoRI launches to enable more strategic, open, diverse, and inclusive research
We’re thrilled to announce the launch of the Research on Research Institute (RoRI) – an international consortium of research funders, academic institutions, and technologists working to champion the latest approaches to research on research.

Co-founded by the Wellcome Trust, the universities of Sheffield and Leiden, and Digital Science, the RoRI consortium will undertake transformative and translational research on research (also known as meta-research, science of science or meta-science). By analysing research systems and experimenting with decision and evaluation data, tools and frameworks, we aim to advance more strategic, open, diverse and inclusive research.

In support of its overall vision for transformative and translational research on research, RoRI has five objectives:
:: To support, expand and build capacity for interdisciplinary, mixed-methods research on research (RoR) in the UK and internationally;
:: To connect academic capabilities to the data and analytical resources of Wellcome, Digital Science and RoRI’s wider consortium of strategic partners;
:: To co-design, experiment and apply new tools, indicators, funding modes, prioritisation and evaluation frameworks;
:: To critically evaluate RoR methods and support engagement with data and evidence about research systems by decision makers and society;
:: To create an independent space for learning, networking and collaboration between researchers, policymakers, funders & technologists.

RoRI will be based for an initial two-year incubation phase at Wellcome’s offices in London. To date, eleven strategic partners have expressed their interest in becoming part of the RoRI consortium, including private foundations, academic research institutions, and public funding agencies from eight countries – Austria, Canada, Denmark, Germany, India, Netherlands, Switzerland, and the USA – and one pan-African partner, the African Academy of Sciences.

Together, the consortium will codesign projects and share data to inform comparative analysis of research systems and cultures, and develop, test and apply novel approaches to decision-making, prioritisation, allocation and evaluation….

RoRI Working Paper No.1
Supporting priority setting in science using research funding landscapes
posted on 29.09.2019,
RoRI Institute :: Ludo Waltman Ismael Rafols Nees Jan van Eck Alfredo Yegros Yegros
In this working paper, we describe how to map research funding landscapes in order to support research funders in setting priorities. Based on data on scientific publications, a funding landscape highlights the research fields that are supported by different funders. The funding landscape described here has been created using data from the Dimensions database. It is presented using a freely available web-based tool that provides an interactive visualization of the landscape. We demonstrate the use of the tool through a case study in which we analyze funding of mental health research.


Sabin Vaccine Institute [to 5 Oct 2019]
Statements and Press Releases
Sabin Vaccine Institute Receives $20.5 Million from BARDA with Potential of up to $128 Million to Develop Ebola Sudan and Marburg Vaccines
Tuesday, October 1, 2019
WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) today announced a funding award of $20.5 million with options for an additional $107.5 million from the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services. Under the terms of this agreement, the full program is expected to advance development of clinical-stage monovalent vaccines against Ebola Sudan and Marburg viruses through Phase 2 clinical trials…


UNAIDS [to 5 Oct 2019]
Selected Press Releases/Reports/Statements
3 October 2019
How London’s first dedicated HIV ward changed the AIDS response


UNICEF [to 5 Oct 2019]
Selected Statements, Press Releases, Reports
Press release
1,000 Ebola survivors in the Democratic Republic of the Congo
Joint Press Release by the UN Emergency Ebola Response Coordinator, World Health Organization, World Food Programme, UNICEF and Save the Children
[See Emergencies above for detail]


Vaccination Acceptance Research Network (VARN) [to 5 Oct 2019]
No new digest content identified.


Vaccine Confidence Project [to 5 Oct 2019]
No new digest content identified.


Vaccine Education Center – Children’s Hospital of Philadelphia [to 5 Oct 2019]
No new digest content identified.


Wellcome Trust [to 5 Oct 2019]
News | 3 October 2019
Stephen Caddick to step down as Director of Innovations at Wellcome
Stephen has made a very significant contribution to advancing Wellcome’s mission over the past five years, including building the Innovations team and developing the Innovations strategy. Wellcome will continue with the strategy, which has approval from the Board, as originally planned.

News | 2 October 2019
Danny Truell (1963-2019): five decisions that made the modern Wellcome
Danny Truell, who died this week, served as Wellcome’s Chief Investment Officer (CIO) for more than a decade and helped make Wellcome what it is today. Nick Moakes, Wellcome’s current CIO, pays tribute to Danny’s brilliance.


Why We Vaccinate [to 5 Oct 2019]
No new digest content identified.


The Wistar Institute [to 5 Oct 2019]
Press Release Oct. 3, 2019
Targeting a Novel Regulator of Mitochondrial Cell Death Delivers Anticancer Activity in Preclinical Studies
PHILADELPHIA — (Oct. 3, 2019) — A novel anticancer molecule created by researchers at The Wistar Institute showed therapeutic activity in preclinical models of various cancer types. This cell-permeable peptidomimetic was designed to disrupt a newly identified protein complex involving mitochondrial fission factor (MFF) and the voltage-dependent anion channel-1 (VDAC1), which regulates mitochondrial cell death. These results appeared online in the journal Cancer Research.

Press Release Oct. 1, 2019
NIH New Innovator Award Given to Wistar Researcher to Unravel the Metabolic Link Between Diet, Alcohol Consumption and Cancer
PHILADELPHIA — (October 1, 2019) — The National Institutes of Health (NIH) today announced that Zachary T Schug, Ph.D., assistant professor in the Molecular & Cellular Oncogenesis Program at The Wistar Institute, was awarded the prestigious NIH Director’s New Innovator Award in support of his research on the link between a high sugar/fat diet, alcohol use and cancer.


World Organisation for Animal Health (OIE) [to 5 Oct 2019]
No new digest content identified.





ARM [Alliance for Regenerative Medicine] [to 5 Oct 2019]
October 2, 2019
The Alliance for Regenerative Medicine Announces Election of 2020 ARM Officers, Executive Committee, and Board of Directors


BIO [to 5 Oct 2019]
No new digest content identified.


DCVMN – Developing Country Vaccine Manufacturers Network [to 5 Oct 2019]
DCVMN 20th Annual General Meeting
21 October 2019 to 23 October 2019
Rio de Janeiro / Brazil


IFPMA [to 5 Oct 2019]
Selected Press Releases, Statements, Publications
No new digest content identified.


PhRMA [to 5 Oct 2019]
Selected Press Releases, Statements